The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial

Zendehdel, Abolfazl; Ansari, Mohsen; Khatami, Farnaz; Mansoursamaei, Shapour; Dialameh, Hossein

doi:10.1016/j.clnu.2020.11.005

Cited by 8 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have demonstrated the deficiency of vitamin D is an important risk factor of BPH, and exogenous vitamin D is effective for the treatment of BPH [ 14 – 16 ]. Our study is the first to provide in vitro evidence to support these clinical findings in vivo.…”

Section: Discussionmentioning

confidence: 99%

“…Although there has been a randomized controlled trial using vitamin D supplementation in the treatment of BPH symptoms [ 16 ], some animal experiments may make our in vitro data more convincing. This is a limitation of the present study.…”

Section: Discussionmentioning

confidence: 99%

“…Accumulating evidence indicates that low vitamin D, especially the active 25-hydroxyvitamin D (25-OH D), is deficient in BPH patients and may be closely associated with the disease pathophysiologic processes [ 14 , 15 ]. More importantly, a recent randomized controlled trial uncovered that vitamin D supplementation is effective in reducing prostate volume and PSA levels, as well as improving BPH symptoms [ 16 ]. However, there has been no enough in vitro evidence to clarify the mechanisms of 25-OH D in reversing the BPH pathological process to support the findings of the in vivo data.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence

Chen

Liu

et al. 2021

Disease Markers

View full text Add to dashboard Cite

The pathogenesis of benign prostatic hyperplasia (BPH) is extremely complicated which involving the multiple signaling pathways. The deficiency of vitamin D is an important risk factor for BPH, and exogenous vitamin D is effective for the treatment of BPH. In this study, we provided in vitro mechanical evidence of vitamin D as a treatment for BPH using BPH-1, WPMY-1, and PBMC cells. We found that 25-hydroxyvitamin D (25-OH D) level is decreased in BPH and closely correlated with age, prostate volume, maximum flow, international prostate symptom score, and prostate-specific antigen of the BPH patients. We further revealed that 25-OH D ameliorated TGF-β1 induces epithelial-mesenchymal transition (EMT) of BPH-1 cells and proliferation of WPMY-1 cells via blocking TGF-β signaling. Moreover, 25-OH D was able to block NF-κB signaling in PBMCs of BPH patients and STAT3 signaling in BPH cells to relieve inflammation. 25-OH D also protects BPH cells from inflammatory cytokines selected by PBMCs. Finally, we uncovered that 25-OH D alleviated prostate cell oxidative stress by triggering Nrf2 signaling. In conclusion, our data verified that 25-OH D regulated multiple singling pathways to restrain prostate cell EMT, proliferation, inflammation, and oxidative stress. Our study provides in vitro mechanical evidence to support clinical use of vitamin D as a treatment for BPH.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence

Chen

Liu

et al. 2021

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Lockdowns and curfews lowered mean serum 25(OH)D concentration, thus, significantly increasing the invulnerability to the SARS-CoV-2 virus, its complications, and deaths [ 26 , 27 ]. Nutritional status is one of the critical aspects responsible for overall health and well-being, including maintaining proper immune system functioning [ 17 , 28 ]. In addition to vitamin D, other essential micronutrients, such as zinc, magnesium, omega-3 fatty acids, quercetin, etc., are also necessary to optimise the functions of the endocrine system.…”

Section: Vitamin D—serum 25(oh)d Concentrations Necessary To Overcome...mentioning

confidence: 99%

“…In several RCTs, vitamin D has also been administered every two weeks with successful clinical outcomes [ 28 , 134 , 135 , 136 , 137 , 138 , 139 ]. However, to efficiently control infections or any other disorder, as described above, it is recommended to administer vitamin D daily or once a week; however, not to increase the frequency of administration for more than ten days.…”

Section: Doses Of Vitamin D Necessary To Boost Serum 25(oh)dmentioning

confidence: 99%

Rapidly Increasing Serum 25(OH)D Boosts the Immune System, against Infections—Sepsis and COVID-19

Wimalawansa¹

2022

Nutrients

View full text Add to dashboard Cite

Vitamin D deficiency is a global public health problem, a pandemic that commonly affects the elderly and those with comorbidities such as obesity, diabetes, hypertension, respiratory disorders, recurrent infections, immune deficiency, and malignancies, as well as ethnic minorities living in temperate countries. The same groups were worst affected by COVID-19. Since vitamin D deficiency weakens the immune system, it increases the risk of infections, complications, and deaths, such as from sepsis and COVID-19. Deficiency can be remedied cost-effectively through targeted food fortification, supplementation, and/or daily safe sun exposure. Its endocrine functions are limited to mineral metabolism, musculoskeletal systems, specific cell membrane interactions, and parathyroid gland functions. Except for the rapid, endocrine, and cell membrane-based non-genomic functions, all other biological and physiological activities of vitamin D depend on the adequate intracellular synthesis of 1,25(OH)2D (calcitriol) in peripheral target cells via the genome. Calcitriol mediates autocrine (intracrine) and paracrine signalling in immune cells, which provides broader, protective immune functions crucial to overcoming infections. The synthesis of 1,25(OH)2D (calcitriol) in peripheral target cells is dependent on diffusion and endocytosis of D3 and 25(OH)D from the circulation into them, which requires maintenance of serum 25(OH)D concentration above 50 ng/mL. Therefore, in acute infections such as sepsis and respiratory infections like COVID-19, it is necessary to rapidly provide its precursors, D3 and 25(OH)D, through the circulation to generate adequate intracellular calcitriol. Immune defence is one of the crucial non-hormonal functions of vitamin D. A single oral (bolus) dose or divided upfront loading doses between 100,000 and 500,000 IU, using 50,000 IU vitamin D3 increase the serum 25(OH)D concentrations to a therapeutic level of above 50 ng/mL that lasts between two to three months. This takes three to five days to raise serum 25(OH)D. In contrast, a single oral dose of calcifediol (0.014 mg/kg body weight) can generate the needed 25(OH)D concentration within four hours. Considering both D3 and 25(OH)D enter immune cells for generating calcitriol, using the combination of D3 (medium-term) and calcifediol (immediate) is cost-effective and leads to the best clinical outcome. To maximise protection against infections, particularly to reduce COVID-19-associated complications and deaths, healthcare workers should advise patients on safe sun exposure, adequate vitamin D supplementation and balanced diets containing zinc, magnesium, and other micronutrients to support the immune system. Meanwhile, governments, the World Health Organisation, the Centers for Disease Control, and governments should consider similar recommendations to physicians and the public, change the outdated vitamin D and other micronutrient recommendations directed to their population, and organise targetted food fortification programs for the vulnerable groups. This article discusses a rational approach to maintaining a sustained serum 25(OH)D concentration above 50 ng/mL, necessary to attain a robust immune system for overcoming infections. Such would cost-effectively improve the population’s health and reduce healthcare costs. It also describes three cost-effective, straightforward protocols for achieving and sustaining therapeutic serum 25(OH)D concentrations above 50 ng/mL (>125 nmol/L) to keep the population healthy, reduce absenteeism, improve productivity, and lower healthcare costs.

show abstract

Smartphone‐Based Free‐to‐Total Prostate Specific Antigen Ratio Detection System Using a Colorimetric Reaction Integrated with Proximity‐Induced Bio‐Barcode and CRISPR/Cas12a Assay

Luo,

Zhou,

Zhan

et al. 2024

Small

View full text Add to dashboard Cite

The free‐to‐total prostate‐specific antigen (f/t‐PSA) ratio is of great significance in the accurate diagnosis of prostate cancer. Herein, a smartphone‐based detection system is reported using a colorimetric reaction integrated with proximity‐induced bio‐barcode and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas12a assay for f/t‐PSA ratio detection. DNA/antibody recognition probes are designed to bind f‐PSA or t‐PSA and induce the release of the DNA bio‐barcode. The CRISPR/Cas12a system is activated by the DNA bio‐barcode to release Ag+ from the C‐Ag+‐C structure of the hairpin DNA. The released Ag+ is used to affect the tetramethylbenzidine (TMB)‐H2O2‐based colorimetric reaction catalyzed by Pt nanoparticles (NPs), as the peroxidase‐like activity of the Pt NPs can be efficiently inhibited by Ag+. A smartphone with a self‐developed app is used as an image reader and analyzer to analyze the colorimetric reaction and provide the results. A limit of detection of 0.06 and 0.04 ng mL−1 is achieved for t‐PSA and f‐PSA, respectively. The smartphone‐based method showed a linear response between 0.1 and 100 ng mL−1 of t‐PSA or f‐PSA. In tests with clinical samples, the smartphone‐based method successfully diagnosed prostate cancer patients from benign prostatic hyperplasia patients and healthy cases with high sensitivity and specificity.

show abstract

The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial

Cited by 8 publications

References 26 publications

Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence

Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence

Rapidly Increasing Serum 25(OH)D Boosts the Immune System, against Infections—Sepsis and COVID-19

Smartphone‐Based Free‐to‐Total Prostate Specific Antigen Ratio Detection System Using a Colorimetric Reaction Integrated with Proximity‐Induced Bio‐Barcode and CRISPR/Cas12a Assay

Contact Info

Product

Resources

About